SINO MEDICAL SCIENCES TECHNOLOGY INC. Sino Medical Sciences Technology Inc. Stock
Equities
688108
CNE100003NY2
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.01 CNY | -0.77% |
|
+4.40% | -28.21% |
| Jun. 07 | Sino Medical Sciences Technology Board Elects Chairman | MT |
| May. 29 | China Approves Sino Medical's Intracranial Stent System | MT |
| Sales 2024 * | 475M 65.34M | Sales 2025 * | 689M 94.77M | Capitalization | 3.65B 503M |
|---|---|---|---|---|---|
| Net income 2024 * | 11M 1.51M | Net income 2025 * | 63M 8.67M | EV / Sales 2024 * | 7.69 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 5.3 x |
| P/E ratio 2024 * |
300
x | P/E ratio 2025 * |
60.1
x | Employees | 652 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66.22% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.77% | ||
| 1 week | +4.40% | ||
| Current month | +0.78% | ||
| 1 month | -17.94% | ||
| 3 months | -25.84% | ||
| 6 months | -25.66% | ||
| Current year | -28.21% |
1 week
8.83
9.34
1 month
8.5110.91
Current year
7.4413.40
1 year
7.4414.85
3 years
4.6014.85
5 years
4.6043.60
10 years
4.6043.60
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Hua Sun
CEO | Chief Executive Officer | 63 | 07-09-20 |
Li Hua Shen
DFI | Director of Finance/CFO | 52 | 12-12-31 |
Wen Tian
BRD | Director/Board Member | 41 | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rui Li
BRD | Director/Board Member | 46 | 20-12-29 |
Yan Gao
BRD | Director/Board Member | 58 | 20-06-18 |
Jian Hua Sun
CEO | Chief Executive Officer | 63 | 07-09-20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-02 | 9.01 | -0.77% | 2,984,958 |
| 24-07-01 | 9.08 | +1.57% | 3,562,278 |
| 24-06-28 | 8.94 | 0.00% | 3,945,364 |
| 24-06-27 | 8.94 | -3.04% | 4,926,332 |
| 24-06-26 | 9.22 | +6.84% | 6,523,818 |
End-of-day quote Shanghai S.E., July 01, 2024
More quotes
Sino Medical Sciences Technology Inc is a China-based company mainly engaged in the research, development, production and sales of high-end interventional medical devices. The Company's product pipeline covers the field of interventional therapy such as cardiovascular, cerebrovascular, and structural heart disease. The Company's main products include coronary drug stent system and balloon dilatation catheters. The Company conducts its businesses within the domestic market and overseas markets, and it has subsidiaries in Beijing, China, Hong Kong, China, the United States, Japan, the Netherlands, and France.
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
9.01
CNY
Average target price
12
CNY
Spread / Average Target
+33.19%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -28.21% | 512M | |
| +11.25% | 127B | |
| -8.63% | 10.76B | |
| -18.88% | 7.06B | |
| +48.07% | 6.5B | |
| -34.82% | 3.99B | |
| +8.47% | 3.44B | |
| -20.30% | 2.45B | |
| -19.41% | 1.89B | |
| -20.90% | 1.75B |
- Stock Market
- Equities
- 688108 Stock
